AXGN Stock Price and Chart — BIVA:AXGN
This page provides a comprehensive overview of Axogen, Inc. (AXGN) stock, traded on BIVA. It includes key financial stats such as market capitalization, revenue, and EPS, along with company information and employee data. The article also features analyst ratings, investment ideas, and details on ETFs holding Axogen stock, offering a complete picture for potential investors.
Tocqueville Asset Management L.P. Takes $8.03 Million Position in AxoGen, Inc. $AXGN
Tocqueville Asset Management L.P. has acquired a new position in AxoGen, Inc. (NASDAQ:AXGN), purchasing 173,900 shares valued at approximately $8.03 million. Despite institutional investors owning over 80% of the company and a "Moderate Buy" consensus rating from analysts, AxoGen remains unprofitable, with insiders selling significant amounts of stock. The company recently reported quarterly revenue of $69.73 million and adjusted earnings of $0.12 per share, matching earnings expectations while exceeding revenue estimates.
Axogen stock reaches 52-week high at 50.0 USD
Axogen Inc. (AXGN) has reached a new 52-week high of $50.00, reflecting a 222.92% growth over the past year and strong market sentiment. Despite this achievement, InvestingPro analysis suggests the stock is overvalued. The company recently reported significant revenue growth of 23% in Q2 2026, surpassing analyst estimates, leading to increased price targets from H.C. Wainwright and Citizens.
Rice Hall James & Associates LLC Invests $3.41 Million in AxoGen, Inc. $AXGN
Rice Hall James & Associates LLC acquired a new stake of 73,903 shares in AxoGen, Inc. ($AXGN) during the second quarter, valued at approximately $3.41 million. Institutional investors collectively own 80.29% of AxoGen, while insider activity shows recent sales totaling $4.48 million. Analysts maintain a "Moderate Buy" rating for AxoGen with an average target price of $51.00, following the company's Q2 earnings report which met EPS estimates and exceeded revenue expectations.
689,833 Shares in AxoGen, Inc. $AXGN Bought by TimesSquare Capital Management LLC
TimesSquare Capital Management LLC has acquired 689,833 shares of AxoGen, Inc. (NASDAQ:AXGN) worth approximately $31.9 million, representing a 1.28% stake in the medical equipment provider. This move contributes to the 80.29% institutional ownership of the company. Despite recent insider selling, analysts maintain a "Moderate Buy" rating for AxoGen, with a consensus price target of $51.
Axogen director Amy Wendell sells $646k in shares
Axogen director Amy Wendell sold approximately $646,592 worth of common stock on August 11, 2026, following the exercise of employee stock options. This sale, conducted via a Rule 10b5-1 trading plan, occurred as the stock traded near its 52-week high, despite an InvestingPro analysis suggesting it might be overvalued. The company recently reported strong Q2 2026 revenue growth, exceeding Wall Street estimates, and received raised price targets from analysts.
First Light Asset Management (AXGN) discloses 7.58% Axogen stake for Mathew Arens
First Light Asset Management, LLC and Mathew P. Arens have filed an amended Schedule 13G disclosing their beneficial ownership in Axogen, Inc. First Light Asset Management may be deemed to beneficially own 3,746,380 shares (6.97% of the class), while Mathew P. Arens may be deemed to beneficially own 4,072,910 shares (7.58% of the class). Arens's ownership includes shares controlled through the Manager, direct holdings, and a joint account.
AxoGen, Inc. $AXGN Shares Sold by Wasatch Advisors LP
Wasatch Advisors LP has reduced its stake in AxoGen, Inc. by 30.2%, selling over 560,000 shares but still retaining 1.30 million shares valued at approximately $59.9 million. Despite this sale, institutional investors collectively own 80.29% of the company, and analyst sentiment remains positive with a "Moderate Buy" consensus rating. AxoGen recently reported quarterly revenue of $69.73 million and adjusted earnings of $0.12 per share, meeting EPS estimates and exceeding revenue expectations.
AxoGen (NASDAQ:AXGN) EVP Marc Began Sells 67,500 Shares of Stock
AxoGen EVP Marc Began sold 67,500 shares of company stock for approximately $3.20 million, reducing his direct holdings by over 57%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, AxoGen shares rose, nearing their 52-week high, and the company reported strong quarterly results that met earnings expectations and exceeded revenue estimates.
AxoGen (NASDAQ:AXGN) Director Sells $646,552.26 in Stock
AxoGen Director Amy McBride Wendell sold 13,353 shares of AXGN stock for over $646,000, reducing her total holdings by 11.01%. This sale occurred under a pre-arranged Rule 10b5-1 plan, and comes as AxoGen shares traded up 2.5% to $49.67, near their 52-week high, following strong earnings that met EPS expectations and exceeded revenue estimates.
Axogen Insider Sold Shares Worth $3,195,788, According to a Recent SEC Filing
An insider at Axogen (AXGN) sold shares valued at $3,195,788, as disclosed in a recent SEC filing. This transaction follows another reported insider sale of $646,592 on the same day. Axogen specializes in technologies for peripheral nerve regeneration and repair.
Axogen (AXGN) Is Up 5.4% After Raising 2026 Revenue Outlook Despite Ongoing Losses – Has The Bull Case Changed?
Axogen (AXGN) saw its stock rise by 5.4% after reporting Q2 2026 sales of US$69.73 million and a net loss of US$1.52 million, alongside raising its full-year 2026 revenue outlook to at least US$279 million. This increased guidance signals management's confidence in demand for its nerve repair portfolio despite ongoing losses, while the company continues to invest heavily in capacity and commercialization. The article explores how this updated outlook impacts Axogen's investment narrative, noting its dependence on a single biologic portfolio and the potential influence of regulatory and reimbursement pressures.
Axogen, Inc. SEC Filing (Aug 11, 2026)
This article reports on an SEC Form 144 filing by Axogen, Inc. (AXGN) on August 11, 2026, detailing a proposed sale of 13,353 common shares with an aggregate market value of $643,881.66 through Morgan Stanley Smith Barney LLC. The securities were acquired on the same date through the exercise of stock options. The filing indicates a neutral impact and sentiment according to AI analysis.
Axogen (AXGN) Is Up 5.4% After Raising 2026 Revenue Outlook Despite Ongoing Losses – Has The Bull Case Changed?
Axogen (AXGN) reported higher Q2 2026 revenue of US$69.73 million but increased net losses of US$1.52 million. Despite ongoing losses, the company raised its full-year 2026 revenue outlook to at least US$279 million, leading to a 5.4% stock increase. This updated guidance reinforces the company's growth story in nerve repair solutions, though investors should consider risks like reliance on a single product and regulatory pressures.
Axogen stock hits 52-week high at 47.09 USD By Investing.com
Axogen Inc. has reached a 52-week high of $47.09, trading at $47.11 with a market capitalization of $2.52 billion, reflecting a 231.91% surge over the past year. The company recently reported strong Q2 2026 revenues of $69.7 million, surpassing analyst estimates, which led to H.C. Wainwright raising its price target to $53 and Citizens increasing theirs to $55, both maintaining Buy/Market Outperform ratings.
Axogen, Inc. SEC Filing (Aug 10, 2026)
This article reports on an SEC Form 144 filing by Axogen, Inc. (AXGN) on August 10, 2026, indicating a proposed sale of 67,500 shares with an aggregate market value of $3,134,025. The filing shows that the securities were acquired through the exercise of stock options on the same date and are intended to be sold via Morgan Stanley Smith Barney LLC on NASDAQ. The filing also confirms the filer's representation that they are not aware of any material adverse information not publicly disclosed.
Axogen stock hits 52-week high at 47.09 USD By Investing.com
Axogen Inc. (AXGN) stock reached a new 52-week high of $47.09, trading at $47.11 with a market capitalization of $2.52 billion, representing a 231.91% surge over the past year. InvestingPro analysis indicates the stock is currently overvalued, yet net income is projected to grow, with analysts forecasting profitability. Recent Q2 2026 financial results showed revenue of $69.7 million, exceeding estimates, and analysts have raised price targets for the company.
AxoGen Inc (AXGN) Stock News Today
This article provides an overview of AxoGen Inc (AXGN) stock, including its current price, market capitalization, and a note that more
MFG Wealth Management Inc. Takes $1.20 Million Position in AxoGen, Inc. $AXGN
MFG Wealth Management Inc. recently acquired 25,876 shares of AxoGen, Inc. (NASDAQ:AXGN) totaling approximately $1.20 million in the second quarter. Institutional investors collectively own 80.29% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $51. AxoGen reported strong quarterly revenue of $69.73 million and met EPS expectations of $0.12, although the company currently operates at a negative net margin.
Axogen (AXGN) Q2 2026 Earnings Call Transcript
Axogen (AXGN) reported strong Q2 2026 financial results with revenue up 23.1% year-over-year, driven primarily by significant growth in its Breast segment. The company raised its full-year revenue guidance to at least $279 million, reflecting confidence in its commercial execution and sales force productivity, though it revised its gross margin guidance to at least 73% due to a shift in product mix towards higher-cost breast procedures. Axogen also highlighted strategic investments in imaging technology and ongoing clinical development in prostate repair, emphasizing its commitment to expanding peripheral nerve care.
Axogen, Inc. SEC Filing (Aug 7, 2026)
This article reports on an SEC Form 144 filing by Axogen, Inc. (AXGN) on August 7, 2026. The filing indicates a proposed sale of 14,150 shares with an aggregate market value of $627,552.50, acquired through Restricted Stock Units on June 19, 2026. The filing also notes that 53,761,513 shares are outstanding and the sale is anticipated to occur on NASDAQ.
AxoGen Number of Employees 2026 | Employee Count & Headcount Data
AxoGen (NASDAQ: AXGN) has 652 employees globally as of March 2026, marking a 36.7% growth since 2023. The company is actively hiring with 57 job postings in 2026, and its workforce is primarily concentrated in North America. Despite growth, overall employee sentiment is negative and declining, and the average salary is $112,705.
Analysts Have Made A Financial Statement On Axogen, Inc.'s (NASDAQ:AXGN) Second-Quarter Report
Following its second-quarter report, analysts have updated their forecasts for Axogen, Inc. While revenues for 2026 are now predicted to be higher at US$279.5m, projected losses per share have also increased to US$0.46. Despite these mixed opinions, the consensus price target remains steady at US$53.22, and the company is expected to grow significantly faster than its industry peers.
Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel (NASDAQ:AXGN)
Axogen is evolving from a specialized tissue supplier into a comprehensive nerve care platform, driven by FDA approval, improved reimbursement, and growing clinical evidence. The company reported strong Q2 2026 revenue growth of 23.1% to $69.7M, raising full-year guidance, though gross margin saw a decline. Avance's FDA biologic approval provides 12 years of exclusivity and strengthens Axogen's position as a market leader, requiring sustained growth and operational efficiency to justify its premium valuation.
Axogen, Inc. Stock 12‑Month Price Target Raised to $51.33, Implies 25% Upside
The average 12-month price target for Axogen, Inc. (AXGN) stock has been raised by analysts from $50.78 to $51.33, representing a potential upside of approximately 25% from its July 28 closing price. This new target is based on estimates from 9 analysts, with individual forecasts ranging from $48 to $55 per share. The consensus rating for AXGN remains a "Buy" among 10 covering analysts.
Analysts Have Made A Financial Statement On Axogen, Inc.'s (NASDAQ:AXGN) Second-Quarter Report
Axogen, Inc. (NASDAQ:AXGN) saw its shares rise 6.9% after its second-quarter results, which showed revenues slightly ahead of estimates at US$70m, though statutory losses were 5.0% larger than predicted. Analysts have since updated their forecasts, now predicting 2026 revenues of US$279.5m (an 11% improvement) and a substantial reduction in losses to US$0.46 per share, despite a notable increase in per-share loss estimates. While the consensus price target remained steady at US$53.22, suggesting growing revenues are offsetting concerns about increased losses, the company's expected growth rate is significantly faster than its industry peers.
Press Release: Axogen, Inc. Reports Second Quarter 2026 Financial Results
Axogen, Inc. has released its financial results for the second quarter of 2026. The press release details the company's performance during this period, providing key financial metrics. Further information regarding these results can be found in the attached document.
AXOGEN, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $53 FROM $50
H.C. Wainwright has increased its target price for AXOGEN, INC. (AXGN) shares from $50 to $53. This adjustment suggests a positive outlook from the financial firm regarding the company's future performance.
Vanguard Capital Management (AXGN) discloses 4.99% Axogen Inc ownership on Schedule 13G/A
Vanguard Capital Management LLC and its affiliated entities have reported a 4.99% beneficial ownership stake in Axogen Inc, according to an amended Schedule 13G filing. This ownership amounts to 2,654,445 shares of common stock, with Vanguard exercising sole voting power over 396,497 shares and sole dispositive power over all 2,654,445 shares. The filing clarifies that this stake is spread across various Vanguard funds and managed accounts, and no single underlying person holds more than 5% through these holdings.
Axogen (AXGN) Stock Faces Margin Squeeze Despite Strong Revenue Growth
Axogen (AXGN) reported strong Q2 2026 revenue growth of US$69.7m, yet its stock slipped slightly due to a net loss of US$1.5m and a dip in gross margin to 72.7%. While breast neurotization programs are driving revenue, higher-cost grafts are squeezing profitability, challenging the company's path to sustained earnings despite operational leverage from investments.
H.C. Wainwright raises AxoGen stock price target to $53 on guidance
H.C. Wainwright raised its price target on AxoGen (NASDAQ: AXGN) to $53 from $50, maintaining a Buy rating, following strong second-quarter 2026 financial results where revenue exceeded projections. The company also increased its 2026 revenue guidance. Despite the positive analyst sentiment and impressive stock performance, InvestingPro analysis suggests the stock might be overvalued.
Axogen, Inc. 2Q 2026: Revenue $69.73M, EPS ($0.03) — 10-Q Summary
Axogen, Inc. reported its second-quarter 2026 results, showing a 23.1% year-over-year revenue increase to $69.73 million. Despite the revenue growth, the company posted a GAAP net loss of ($1.52M) and diluted EPS of ($0.03), compared to a net income in the prior year. Key business highlights include increased unit volumes, a shift towards higher-cost biologic products, and positive regulatory momentum with FDA BLA approval and new clinical study initiations.
Axogen, Inc. (NASDAQ: AXGN) grows revenue 24.7% and retires debt
Axogen, Inc. reported strong revenue growth for the first half of 2026, with a 24.7% increase year-over-year to $131.188 million, driven by higher unit volumes and pricing. Despite this growth, the company posted a net loss of $21.1 million for the six-month period, primarily due to a $16.849 million loss on the extinguishment of debt. Axogen successfully retired its Oberland credit facility using proceeds from a public stock offering, significantly strengthening its balance sheet with increased cash and investments and eliminating long-term debt.
AxoGen: Q2 Earnings Snapshot
This article provides a snapshot of AxoGen's Q2 earnings. No specific financial details are available in the provided content, but it indicates a focus on their financial performance for the quarter.
Press Release: Axogen, Inc. Reports Second Quarter 2026 Financial Results
Axogen, Inc. has announced its financial results for the second quarter of 2026. The company reported a significant increase in revenue, driven by strong growth in its nerve repair product portfolio. Axogen also updated its full-year guidance, projecting continued expansion.
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Axogen, Inc. reported its second quarter 2026 financial results, achieving $69.7 million in revenue, a 23.1% increase year-over-year. Despite a net loss of $1.5 million, adjusted net income stood at $7.3 million. The company also raised its full-year 2026 revenue guidance to at least $279 million, representing at least 24% growth.
Axogen Inc (AXGN) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Challenges
Axogen Inc (AXGN) reported a 23% year-over-year revenue growth in Q2 2026, driven significantly by the breast market, and increased its full-year revenue guidance. Despite this strong growth and robust financial health with $113.4 million in cash, the company experienced a decrease in gross margin to 72.7% and an increase in operating expenses, leading to a net loss of $1.5 million. Challenges also include delays in Aetna's coverage of their products, impacting future growth prospects.
Axogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
Axogen, Inc. announced its earnings results for the second quarter and first six months of 2026. For Q2 2026, sales increased to $69.
Axogen Inc earnings missed by $0.24, revenue topped estimates
Axogen Inc (NASDAQ: AXGN) reported second-quarter earnings per
Axogen, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2026-07-29
Axogen, Inc. (AXGN) published its Q2 2026 earnings call presentation on July 29, 2026. The company reported an EPS of $0.12, which beat estimates by $0.00, and revenue of $69.73 million, representing a 23.06% year-over-year increase and beating estimates by $2.64 million. The slide deck provides detailed results from their second fiscal quarter.
Nerve Trace imaging begins Phase I trial with Axogen backing
Trace Biosciences announced a strategic investment from Axogen (NASDAQ: AXGN) as part of its Series A financing to advance clinical development of its Nerve Trace near-infrared fluorescence imaging technology. Nerve Trace Dx, the lead candidate, has begun a Phase I trial after receiving FDA IND clearance in December 2025, and the new capital will support planned Phase II and III trials toward a New Drug Application. This technology aims to provide real-time visualization of nerves during surgery, enhancing both protection and repair of peripheral nerves.
Axogen, Inc. (AXGN) Q2 2026 Earnings
Axogen, Inc. (AXGN) reported its Q2 2026 earnings, surpassing both earnings and revenue expectations with an EPS of $0.12 and revenue of $70M. The company also raised its full-year guidance, driven by over
AxoGen: Q2 Earnings Snapshot
This article provides a brief "Q2 Earnings Snapshot" for AxoGen, offering a concise overview of the company's financial performance during the second quarter. The content effectively serves as a headline to attract readers interested in AxoGen's recent earnings.
Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
Trace Biosciences has received a strategic investment from Axogen, the global leader in surgical peripheral nerve function solutions. This investment is part of Trace's Series A financing and will support the clinical development of Nerve Trace, a near-infrared fluorescence imaging technology designed to visualize nerves during surgery. Nerve Trace aims to enhance surgical precision by allowing surgeons to identify and avoid nerves, or to localize and assess injured nerves more effectively.
How Axogen Inc. (AXGN) Affects Rotational Strategy Timing
Axogen Inc. (NASDAQ: AXGN) is showing divergent sentiment across all horizons, suggesting choppy conditions with a mid-channel oscillation pattern. The article presents institutional trading strategies including a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, highlighting a significant 44.4:1 risk-reward setup. AI-generated signals provide multi-timeframe analysis, indicating neutral near-term, weak mid-term, and strong long-term outlooks.
Axogen earnings on deck as nerve repair reimbursement gains gather steam
Axogen Inc. is set to release its second-quarter earnings, with analysts expecting 12 cents per share on $67.1 million in revenue. Investors are keenly watching how a recent CMS outpatient reimbursement reclassification, which boosted rates by 40% starting January 1, 2026, is impacting procedure volume and revenue growth. Additionally, the company's ability to sustain margin expansion and the commercial performance of its recently FDA-approved biologic, Avance, will be key areas of focus.
Axogen earnings on deck as nerve repair reimbursement gains gather steam
Axogen Inc. is set to report its second-quarter earnings, with analysts expecting revenue growth driven by recent reimbursement changes for nerve repair procedures. Investors will be closely watching if the new CMS outpatient reimbursement reclassification, which took effect in January 2026, is leading to increased procedure volume and revenue acceleration. The company's gross profit margin and the commercial performance of its FDA-approved Avance biologic will also be key focus areas.
AxoGen Inc (AXGN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of AxoGen Inc (AXGN), noting its current valuation score is 8.49, ranking 91 out of 199 in its industry. The company's P/E ratio stands at -64.71, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by AxoGen Inc.
234,495 Shares in AxoGen, Inc. $AXGN Acquired by SummitTX Capital L.P.
SummitTX Capital L.P. recently acquired 234,495 shares of AxoGen, Inc. (NASDAQ:AXGN) totaling approximately $7.8 million, now owning 0.44% of the company. Institutional investors collectively hold 80.29% of AxoGen's stock, and while analysts generally rate it a "Moderate Buy" with an average target price of $46.50, the company's recent earnings per share missed expectations despite exceeding revenue forecasts. Additionally, company directors sold a combined 29,041 shares valued at $1.27 million in the last quarter.
First Light Asset Management LLC Has $132.61 Million Stock Holdings in AxoGen, Inc. $AXGN
First Light Asset Management LLC recently reduced its stake in AxoGen, Inc. by 23.5% but still holds 4 million shares valued at $132.61 million, making it their largest holding. Despite missing EPS estimates, AxoGen reported strong revenue, and analysts maintain a "Moderate Buy" rating with a consensus price target of $46.50. Institutional ownership is high at 80.29%, although company insiders have sold approximately $1.27 million in stock recently.
